BamSEC and AlphaSense Join Forces
Learn More

Avalo Therapeutics Inc.

NASDAQ: AVTX    
Share price (1/8/25): $7.03    
Market cap (1/8/25): $73.1 million

Material Contracts Filter

EX-10.1
from 8-K 13 pages On Behalf of Avalo Therapeutics, Inc., a Delaware Corporation (The “Company”), We Are Pleased to Formalize for You the Terms of Your Employment With the Company as Set Forth in This Agreement (The “Agreement”). Please Note That This Offer of Employment Is Contingent Upon a Clearance of a Background Check and Two Satisfactory Professional References
12/34/56
EX-10.4
from 10-Q 3 pages Avalo Therapeutics, Inc. Non-Employee Director Compensation Policy Amended Effective July 1, 2024
12/34/56
EX-10.2
from 8-K 11 pages Avalo Therapeutics, Inc. Amended and Restated 2016 Employee Stock Purchase Plan Adopted by the Board of Directors: June 6, 2024 Approved by the Stockholders: August 13, 2024
12/34/56
EX-10.1
from 8-K 23 pages Avalo Therapeutics, Inc. Fourth Amended and Restated 2016 Equity Incentive Plan Adopted by the Board of Directors: June 6, 2024 Approved by the Stockholders: August 13, 2024
12/34/56
EX-10.1
from 8-K 13 pages June 1, 2024 Mittie Doyle, MD Dear Mittie
12/34/56
EX-10.2
from 8-K 2 pages Amendment to Employment Agreement
12/34/56
EX-10.1
from 8-K 13 pages Paul Varki Dear Paul: On Behalf of Avalo Therapeutics, Inc., a Delaware Corporation (The “Company”), We Are Pleased to Formalize for You the Terms of Your Employment With the Company as Set Forth in This Agreement (The “Agreement”). Please Note That This Offer of Employment Is Contingent Upon a Clearance of a Background Check and Two Satisfactory Professional References
12/34/56
EX-10.3
from 10-Q 3 pages Certain Information Identified With the Mark “(***)” Has Been Excluded From This Exhibit Because Such Information Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. First Amendment to License Agreement Between Flame Biosciences, Inc. and Eli Lilly and Company
12/34/56
EX-10.2
from 10-Q 43 pages License Agreement by and Between Flame Biosciences, Inc. and Eli Lilly and Company Certain Information Identified With the Mark “(***)” Has Been Excluded From This Exhibit Because Such Information Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. License Agreement
12/34/56
EX-10.1
from 10-Q 40 pages Certain Information Identified With the Mark “(***)” Has Been Excluded From This Exhibit Because Such Information Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Asset Purchase Agreement
12/34/56
EX-10.2
from 8-K 25 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 51 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 5 pages Via Electronic and Regular Mail Avalo Therapeutics, Inc. (F/K/a Cerecor Inc.) 540 Gaither Road, Suite 400 Rockville, MD 20850 Attn: Garry Neil, Chief Executive Officer Re: Avalo Therapeutics, Inc. (F/K/a Cerecor Inc.) Payoff Letter Dear Mr. Neil
12/34/56
EX-10.1
from 8-K 8 pages Third Forbearance Agreement
12/34/56
EX-10.1
from 8-K 8 pages Second Forbearance Agreement
12/34/56
EX-10.1
from 8-K 7 pages Forbearance Agreement
12/34/56
EX-10.1
from 8-K 6 pages In Consideration of the Foregoing, the Company and the Stockholders Agree as Follows
12/34/56
EX-10.3
from 10-Q 27 pages Purchase Agreement by and Among Avalo Therapeutics, Inc., and Es Therapeutics, LLC Dated as of November 4, 2022
12/34/56
EX-10.1
from 10-Q 46 pages Certain Information Identified With the Mark “(***)” Has Been Excluded From This Exhibit Because Such Information Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. License Agreement
12/34/56
EX-10.1
from 8-K 2 pages [Signature Page Follows] 1
12/34/56